The earnings call highlighted significant strategic restructuring, cost-saving measures, and a focused pipeline to strengthen Sarepta's financial position and future growth. However, challenges such as workforce reduction, hesitancy in ELEVIDYS adoption, and suspension of nonambulatory ELEVIDYS shipments present significant hurdles.

Company Guidance

During the call, Sarepta provided detailed guidance on its strategic restructuring and financial outlook. The company plans to reduce costs by $900 million through 2027 while maintaining profitability and a cash flow-positive status, ensuring it can address its financial obligations, including the retirement of its 2027 convertible note. Sarepta's strategy focuses on supporting its four approved therapies, including the gene therapy ELEVIDYS, and advancing a targeted pipeline of high-impact development programs for rare diseases. The company aims to achieve annual revenues of $500 million from ELEVIDYS and $900 million from its PMO franchise, totaling over $1.4 billion from its Duchenne franchise. Sarepta also plans to reduce its workforce by approximately 36%, translating to about 500 employees, to align resources with its refocused pipeline. The company ended the quarter with $850 million in cash and cash equivalents, reflecting a $203 million increase over the previous quarter.

ELEVIDYS Revenue Contribution

ELEVIDYS generated $282 million in revenue in Q2 2025, contributing significantly to the total net product revenue.

Positive Cash Flow and Financial Position

Ended the quarter with $850 million in cash and equivalents, an increase of $203 million over Q1, ensuring financial flexibility.

Cost Reduction and Strategic Restructuring

Plans to reduce ongoing spending by about $900 million through 2027, with an expected $400 million annual cost savings starting in 2026.

Pipeline Focus and Expansion

Focused pipeline on high-impact programs like FSHD, DM1, SCA2, and Huntington's disease, ensuring funding for these developments.

ELEVIDYS Label Update

Agreed with FDA to include a black box warning for ELEVIDYS, which resolves material issues for the ambulant portion of the label.

Sarepta Therapeutics (SRPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.63 / -	0.34	―	―	―
Aug 06, 2025	2025 (Q2)	0.83 / 1.89	0.07	2600.00% (+1.82)	―	―
May 06, 2025	2025 (Q1)	-3.21 / -4.60	0.37	-1343.24% (-4.97)
Feb 26, 2025	2024 (Q4)	1.88 / 1.50	0.47	219.15% (+1.03)
Nov 06, 2024	2024 (Q3)	-0.07 / 0.34	-0.46	173.91% (+0.80)	―
Aug 07, 2024	2024 (Q2)	-0.13 / 0.07	-0.27	125.93% (+0.34)	―
May 01, 2024	2024 (Q1)	0.01 / 0.37	-5.86	106.31% (+6.23)	―
Feb 28, 2024	2023 (Q4)	0.07 / 0.47	-1.24	137.90% (+1.71)	―
Nov 01, 2023	2023 (Q3)	-1.22 / -0.46	-2.94	84.35% (+2.48)	―
Aug 02, 2023	2023 (Q2)	-1.78 / -0.27	-2.65	89.81% (+2.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$16.26	$17.96	+10.46%
May 06, 2025	$46.75	$36.72	-21.45%
Feb 26, 2025	$106.86	$103.06	-3.56%
Nov 06, 2024	$127.97	$120.42	-5.90%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.